CGEM

Cullinan Therapeutics, Inc. NASDAQ Listed Jan 8, 2021

Healthcare ·Medical - Pharmaceuticals ·US · cullinantherapeutics.com

$14.99

After hrs $15.00 +0.07%

Mkt Cap $921.2M

52w Low $5.68 84.2% of range 52w High $16.74

50d MA $14.25 200d MA $10.35

P/E (TTM) -3.6x

EV/EBITDA -2.2x

P/B 1.9x

Debt/Equity 0.0x

ROE -53.8%

P/FCF -3.5x

RSI (14) —

ATR (14) —

Beta -0.11

50d MA $14.25

200d MA $10.35

Avg Volume 797.3K

About

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 10, 2026	AMC	-0.80	-0.77	+3.8%	14.91	-1.6%	-4.0%	-6.4%	-9.5%	-5.9%	-9.9%	—
Nov 6, 2025	AMC	-0.95	-0.77	+18.9%	7.35	-1.5%	-2.2%	+1.2%	+6.1%	+13.6%	+12.5%	—
Aug 7, 2025	AMC	-0.83	-1.07	-28.9%	7.03	+0.1%	+3.8%	+0.9%	+3.4%	+8.7%	+7.8%	—
May 8, 2025	AMC	-0.78	-0.74	+5.1%	7.77	-0.1%	-3.0%	+1.8%	-1.9%	-8.2%	-6.8%	—
Feb 27, 2025	AMC	-0.75	-0.73	+2.7%	8.61	+0.5%	-1.4%	-7.1%	-5.6%	-2.1%	-1.2%	—
Nov 7, 2024	AMC	-0.78	-0.69	+11.5%	15.58	+1.7%	+2.8%	+10.8%	+2.8%	+1.3%	-1.8%	—
Aug 8, 2024	AMC	-0.73	-0.75	-2.7%	16.38	+3.2%	+2.4%	-0.5%	-0.5%	-0.9%	+3.2%	—
May 15, 2024	AMC	-0.90	-0.86	+4.4%	26.72	+0.3%	-10.9%	-13.3%	-10.3%	-13.3%	-13.4%	—
Mar 14, 2024	AMC	-0.96	-0.54	+43.8%	16.91	-0.2%	-5.8%	-9.4%	-8.3%	-8.2%	-3.4%	—
Nov 8, 2023	AMC	-0.91	-0.91	+0.0%	9.94	+1.6%	-3.5%	-8.6%	-11.8%	-4.5%	-10.8%	—
Aug 10, 2023	AMC	-0.99	-0.82	+17.2%	10.29	+0.5%	+5.1%	-0.2%	-0.8%	-2.6%	-2.0%	—
May 11, 2023	AMC	-0.84	-1.42	-69.0%	9.62	-9.0%	+1.5%	+3.3%	-5.1%	-8.2%	-8.5%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 28	HC Wainwright & Co.	Maintains	Buy → Buy	—	$13.25	$13.40	+1.1%	-3.3%	-3.0%	-1.5%	+1.4%	—
Mar 11	Wedbush	Maintains	Outperform → Outperform	—	$14.91	$14.67	-1.6%	-4.0%	-6.4%	-9.5%	-5.9%	-9.9%
Jan 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$10.94	$10.71	-2.1%	+1.8%	-0.4%	-3.0%	-1.9%	-0.6%
Dec 9	Wedbush	Maintains	Outperform → Outperform	—	$12.44	$12.44	+0.0%	-0.6%	+0.2%	-0.5%	-4.2%	-13.0%
Nov 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.45	$8.63	+2.1%	+3.2%	+12.1%	+53.0%	+39.5%	+38.9%
Sep 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.62	$6.57	-0.8%	-1.4%	-4.1%	-5.0%	-10.4%	-4.2%
Sep 10	BTIG	Maintains	Buy → Buy	—	$6.83	$6.77	-0.9%	-5.3%	-3.1%	-4.4%	-7.0%	-7.9%
Aug 18	Morgan Stanley	Maintains	Overweight → Overweight	—	$7.66	$7.64	-0.3%	+3.8%	-1.0%	-2.5%	+0.1%	+6.9%
May 12	UBS	Maintains	Buy → Buy	—	$7.54	$7.93	+5.2%	+4.9%	+1.1%	-5.4%	-4.0%	-0.5%
Apr 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$7.80	$7.69	-1.4%	-2.4%	+1.2%	+3.8%	+7.3%	+7.4%
Feb 28	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.61	$8.65	+0.5%	-1.4%	-7.1%	-5.6%	-2.1%	-1.2%
Feb 28	Stifel	Maintains	Buy → Buy	—	$8.61	$8.65	+0.5%	-1.4%	-7.1%	-5.6%	-2.1%	-1.2%
Aug 9	Wedbush	Maintains	Outperform → Outperform	—	$16.38	$16.90	+3.2%	+2.4%	-0.5%	-0.5%	-0.9%	+3.2%
Jun 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$23.50	$22.86	-2.7%	-4.1%	-4.7%	-2.8%	-4.1%	-4.7%
May 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$22.65	$22.61	-0.2%	+6.5%	+1.7%	+0.1%	+0.6%	+3.8%
May 16	Wedbush	Maintains	Outperform → Outperform	—	$26.72	$26.79	+0.3%	-10.9%	-13.3%	-10.3%	-13.3%	-13.4%
May 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$26.72	$26.79	+0.3%	-10.9%	-13.3%	-10.3%	-13.3%	-13.4%
Apr 17	JonesTrading	Maintains	Buy → Buy	—	$17.32	$18.01	+4.0%	+3.2%	+4.3%	-9.6%	-9.8%	-3.8%
Apr 17	BTIG	Maintains	Buy → Buy	—	$17.32	$18.01	+4.0%	+3.2%	+4.3%	-9.6%	-9.8%	-3.8%
Apr 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$16.55	$19.87	+20.1%	+4.7%	+8.0%	+9.1%	-5.4%	-5.6%
Mar 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$16.98	$16.79	-1.1%	-0.4%	-6.2%	-9.8%	-8.7%	-8.5%
Aug 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$10.29	$10.34	+0.5%	+5.1%	-0.2%	-0.8%	-2.6%	-2.0%
Jul 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$10.48	$10.41	-0.7%	-1.9%	-4.8%	-4.2%	-1.0%	+9.9%
Jun 5	HC Wainwright & Co.	Maintains	Buy → Buy	—	$10.53	$10.63	+0.9%	+10.6%	+16.7%	+27.3%	+23.5%	+24.5%
May 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.56	$9.54	-0.2%	+5.1%	+7.0%	+7.5%	+6.3%	+10.1%
May 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.62	$8.75	-9.0%	+1.5%	+3.3%	-5.1%	-8.2%	-8.5%
Mar 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	$10.51	$10.61	+1.0%	+3.7%	-0.3%	+2.4%	-2.9%	-2.7%
Mar 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$11.07	$10.93	-1.3%	-1.6%	-0.6%	+3.2%	+1.3%	-1.9%
Feb 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$11.38	$11.26	-1.1%	+1.5%	-2.8%	-0.4%	-3.4%	-3.1%
Feb 3	Morgan Stanley	Maintains	Overweight → Overweight	—	$11.91	$11.84	-0.6%	-1.2%	-4.3%	-3.9%	-3.4%	-4.3%
Nov 21	BTIG	Maintains	Buy → Buy	—	$12.41	$13.10	+5.6%	+2.8%	+6.4%	+8.1%	+7.0%	+1.2%
May 13	SVB Leerink	Maintains	Outperform → Outperform	—	$9.00	$9.33	+3.7%	+18.0%	+20.9%	+33.9%	+26.3%	+20.0%
Mar 18	HC Wainwright & Co.	Maintains	Buy → Buy	—	$12.81	$12.55	-2.0%	+4.1%	+0.1%	-1.5%	-5.9%	-4.6%
Jun 7	Morgan Stanley	Maintains	Overweight → Overweight	—	$33.11	$33.20	+0.3%	+2.3%	+1.0%	-1.5%	-2.7%	-5.2%
Jun 4	SVB Leerink	Maintains	Outperform → Outperform	—	$29.76	$37.59	+26.3%	+11.3%	+13.8%	+12.4%	+9.6%	+8.2%
Jun 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$29.76	$37.59	+26.3%	+11.3%	+13.8%	+12.4%	+9.6%	+8.2%
Apr 27	Morgan Stanley	Upgrade	Equal Weight → Overweight	—	$31.68	$33.70	+6.4%	+9.4%	+4.9%	+3.5%	+2.5%	+8.1%
Apr 19	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$35.20	$35.03	-0.5%	-8.8%	-11.1%	-3.9%	-7.7%	-10.5%
Mar 30	HC Wainwright & Co.	Maintains	Buy → Buy	—	$38.05	$38.02	-0.1%	+4.4%	+9.5%	+8.4%	+7.8%	-7.6%

Recent Filings

8-K

Unknown — 8-K Filing

Cullinan Therapeutics has sufficient cash ($439M runway through 2029) to reach multiple clinical milestones in 2026, reducing near-term financing risk and supporting stock stability despite ongoing development timelines.

Mar 10

Data updated apr 25, 2026 12:58am · Source: massive.com